Use of anakinra in severe COVID-19: A case report

Abstract

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).

Keywords

• Anakinra
• IL-1
• COVID-19
• Treatment
• Biologic